National Cancer Institute
at the National Institutes of Health
Melanoma Trial Results
- Expanding the Playing Field: Immune-Based Therapy Shows Potential for Lung, Other Cancers
(Posted: 06/15/2012) - Results from two early-phase clinical trials presented at the 2012 American Society of Clinical Oncology annual meeting provide further evidence that priming the immune system to attack tumors has potential as a treatment for certain cancers.
- New Therapies Offer Valuable Options for Patients with Melanoma
(Posted: 07/19/2011, Updated: 12/07/2011) - Two phase III clinical trials of new therapies for patients with metastatic melanoma presented in June at the 2011 ASCO conference confirmed that the molecularly targeted agent vemurafenib and the immunotherapy agent ipilimumab (Yervoy™) offer valuable new options for a disease in which effective treatments have been lacking.
- Study Suggests Smaller Melanoma Excision Margins May Be Option for Some Patients
(Posted: 12/02/2011) - A randomized controlled trial of patients with stage IIA–C cutaneous melanoma thicker than 2-mm found that a 2-cm surgical resection margin is sufficient and is as safe for patients as a 4-cm margin in terms of overall survival, according to a report published online October 21 in The Lancet.
- Regular Sunscreen Use May Reduce Invasive Melanoma Risk
(Posted: 12/27/2010) - Regular sunscreen use may reduce the risk of developing melanoma, according to results of a randomized controlled trial that were reported December 6, 2010, in the Journal of Clinical Oncology.
- Targeted Drug for Melanoma Shows Promise in Early Clinical Testing
(Posted: 09/24/2010) - The vast majority of patients with advanced melanoma who received an experimental targeted drug called PLX4032 responded to the treatment in a phase I clinical trial, researchers reported in the August 26, 2010, New England Journal of Medicine.